Leerink Partners on Monopar Therapeutics (MNPR): shares don't reflect 'magnitude of market opportunity'
Tweet Send to a Friend
Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $115.00 price target on Monopar Therapeutics (NASDAQ: MNPR)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
